Free Subscription

  • Access daily briefings and unlimited news articles

Premium

Only $39.95 per year
  • Quarterly magazine and digital
  • Indepth executive interviews
  • Unlimited news and insights
  • Expert opinion and analysis

CSL Behring

CSL Behring Archives

CSL, Calimmune lock $91m deal

Biotechnology companies focus on stem cell therapy.